Core Viewpoint - The report from CICC maintains the revenue forecasts for Yidu Tech (02158) for FY2026 and FY2027, while adjusting the net profit forecasts for FY2026 and FY2027 from -45.69 million to 0.41 million and from 0.41 million to 5.457 million respectively, due to effective cost control [1] Group 1 - The revenue for the first half of FY2026 was in line with expectations, with a reported income of 360 million, representing a year-on-year growth of 8.7%, and a significant reduction in net loss by approximately 72% compared to the same period last year [2] - The company is leveraging "data elements × AI technology" to build a medical AI infrastructure, with revenue from big data platforms and solutions increasing by 14.6% to 153 million, driven by policy support and business opportunities [3] - The health management platform and solutions saw a year-on-year revenue increase of 30.3% to 66.67 million, with the Shenzhen health insurance project surpassing 6.15 million insured individuals by 2025, marking a historical high [3] Group 2 - The company is focused on business optimization, with an improvement in overall gross margin by 1.8 percentage points to 37.4%, and a significant reduction in net loss to 15.76 million, a 72% decrease year-on-year [4] - Cash flow management has improved, with net cash outflow from operating activities reduced by 56% year-on-year [4]

Core Viewpoint - The company, Yidu Tech (02158), has demonstrated healthy growth in its business, achieving a total revenue of RMB 358 million, representing a year-on-year increase of 8.7% [1][1][1] Financial Performance - The adjusted EBITDA for existing business reached approximately RMB 54 million, doubling compared to the same period last year [1][1][1] - The company has nearly achieved breakeven at the accounting level, reaching this key financial milestone about a year earlier than management's previous expectations [1][1][1] Market Activity - On December 3, the company repurchased 392,000 shares at a price of HKD 5.09 per share, with a total repurchase amount of approximately HKD 2 million [1][1][1] Analyst Sentiment - Brokerages are releasing positive signals regarding the company, with Everbright Securities highlighting Yidu Tech's continuous breakthroughs in the AI medical innovation field [1][1][1] - Citigroup has maintained a "Buy" rating for the company, setting a target price of HKD 10, recognizing its core competitiveness and growth potential in the AI healthcare sector [1][1][1]

资本市场层面，券商机构持续释放积极信号。光大证券在跟踪研究报告中指出，医渡科技在 AI医疗创 新领域持续突破，其医疗大模型已初步构建"数据+算法+场景"的飞轮闭环，正加速推动技术在多场景 落地应用。花旗亦发布报告维持对公司的"买入"评级，目标价为10港元，充分认可其在AI医疗赛道的核 心竞争力与成长潜力。 智通财经APP获悉，医渡科技(02158)公告显示，12月3日公司以每股5.09港元的价格回购39.2万股，回购 金额约200万港元。 消息面上，医渡科技于近日发布了2026财年中期业绩并举行了业绩发布会。报告显示，在报告期内，医 渡科技业务保持健康增长，总收入达到人民币3.58亿元，同比增长8.7%。公司的盈利质量与运营效率实 现了显著跨越：现有业务经调整EBITDA约人民币5400万元，较去年同期实现翻倍，会计报表层面几近 盈亏平衡。这一关键财务里程碑的达成，比公司管理层此前预期的时间点提前了约一年。 ...

Group 1 - The company, Yidu Tech (02158.HK), announced the issuance of a total of 1,958,000 shares as part of its share award plan, which represents approximately 0.18% of the total issued shares as of the announcement date, excluding treasury shares [1] - The share issuance is contingent upon acceptance by the three award recipients [1] - The announcement was made on December 3, 2025 [1]

Core Viewpoint - Yidu Tech (02158) announced that on December 3, 2025, the company will grant a total of 1.958 million shares to three reward recipients under its post-IPO share incentive plan, representing approximately 0.18% of all issued shares as of the announcement date, excluding treasury shares, pending acceptance by the recipients [1] Company Summary - Yidu Tech will issue 1.958 million shares as part of its share incentive plan [1] - The shares granted will account for about 0.18% of the total issued shares, excluding treasury shares [1] - The issuance is contingent upon acceptance by the reward recipients [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 根據股份獎勵計劃授出股份獎勵 於2025年12月3日，本公司根據首次公開發售後股份獎勵計劃，通過發行新股份（定 義見上市規則第17章）向3名獎勵承授人授出合共1,958,000股獎勵股份，佔於本公告 日期全部已發行股份（不包括庫存股）約0.18%，惟須待獎勵承授人接納後方可作 實。 已授出獎勵的詳情如下： | 授出日期： | 2025年12月3日 | | --- | --- | | 獎勵承授人數量： | 3名 | | 已授出獎勵數目： | 1,958,000份 | | 獎勵股份代價： | 無 | | 於授出日期股份的 | 每股股份5.10港元，按於授出日期聯交所所報之收市價 | | 市價： | 計算 | – 1 – Yidu Tech Inc. 醫渡科技有限公司 ( 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ) (股份代號：2158) 授出股份獎勵 本公告乃根據上市規則第17.06A、17. ...

Core Viewpoint - The company, Yidu Tech (02158), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1: Share Buyback Details - The company will spend HKD 1.9953 million to repurchase 392,000 shares [1] - The buyback price per share ranges from HKD 5.07 to HKD 5.10 [1]

Group 1 - The company, Yidu Tech (02158), announced a share buyback on December 3, 2025, spending HKD 1.9953 million to repurchase 392,000 shares [1] - The buyback price per share ranged from HKD 5.07 to HKD 5.10 [1]

Core Viewpoint - The company, Yidu Tech (02158.HK), announced a share buyback on December 3, 2023, spending HKD 1.995 million to repurchase 392,000 shares at a price range of HKD 5.07 to 5.10 per share [1] Summary by Category - **Company Actions** - Yidu Tech executed a buyback of 392,000 shares at a total cost of HKD 1.995 million [1] - The repurchase price per share ranged from HKD 5.07 to HKD 5.10 [1]

FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02158 | 說明 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2025年10月31日 | 1,063,856,231 ...